Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia.
about
Wilms tumor 1 mutations in the pathogenesis of acute myeloid leukemiaCancer vaccines and T cell therapyDeveloping strategies in the immunotherapy of leukemiasRecent advance in antigen-specific immunotherapy for acute myeloid leukemiaActive specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trialsStructures of native and affinity-enhanced WT1 epitopes bound to HLA-A0201: Implications for WT1-based cancer therapeuticsSingle-walled carbon nanotubes deliver peptide antigen into dendritic cells and enhance IgG responses to tumor-associated antigensCarbon nanotubes as vaccine scaffoldsImmune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission.A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemiasImpaired B cell immunity in acute myeloid leukemia patients after chemotherapy.Lymphodepletion is permissive to the development of spontaneous T-cell responses to the self-antigen PR1 early after allogeneic stem cell transplantation and in patients with acute myeloid leukemia undergoing WT1 peptide vaccination following chemotTowards an immunosense vaccine to prevent toxoplasmosis: protective Toxoplasma gondii epitopes restricted by HLA-A*0201Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909.Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies.Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses.Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplantGeneration of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia--implications for immunotherapy.An analogue peptide from the Cancer/Testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide.Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicinWilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene.Summit on cell therapy for cancer: The importance of the interaction of multiple disciplines to advance clinical therapy.Supportive care in patients with acute leukaemia: historical perspectives.Strategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantationThe immune microenvironment of myelomaHaematological malignancies: at the forefront of immunotherapeutic innovation.Analysis of the functional WT1-specific T-cell repertoire in healthy donors reveals a discrepancy between CD4(+) and CD8(+) memory formation.WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptidesPeptide Based Vaccine Approaches for Cancer-A Novel Approach Using a WT-1 Synthetic Long Peptide and the IRX-2 Immunomodulatory RegimenApproaching untargetable tumor-associated antigens with antibodies.The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.Wilms tumor 1 peptide vaccination after hematopoietic stem cell transplant in leukemia patients.Targeting the intracellular WT1 oncogene product with a therapeutic human antibody.Understanding CD8+ T-cell responses toward the native and alternate HLA-A*02:01-restricted WT1 epitope.Peptide vaccine therapy for leukemia.Ten years of progress in vaccination against cancer: the need to counteract cancer evasion by dual targeting in future therapies.Clinical peptide vaccination trials for leukemia patients.Vaccination strategies in lymphomas and leukaemias: recent progress.Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia.Next-generation peptide vaccines for advanced cancer.
P2860
Q26744111-297DFE13-FD9A-4162-8262-38C156127D6BQ26995638-B49E3D08-AC9D-450E-B374-1E4CB4B2527EQ26996310-4068F478-FC56-4A0A-9E96-069290886B45Q27005765-4B041CAC-2711-4A39-9FA5-C5A88C77E82DQ27026836-6F2FB912-17D2-4EA3-87A0-502A0585B3A9Q27663300-17E32FC3-935E-462C-A72B-3F555275BC33Q28390624-2A32958A-C9A8-4A40-9263-F409FFB46857Q28392532-0003B2CF-B883-4D5F-93F1-FFE1414629C0Q33593877-2AC86CD0-9332-4810-BC35-357191A6F0C8Q33714727-7BEA51D4-0175-4466-B2DF-2B3AAAA7E85BQ33892358-C51D375D-A243-4541-A37C-76037B6CE511Q34180369-DD87D7A5-2CA8-415B-9A78-A3793876511AQ34458916-26B833F3-0B8F-4735-8EF8-C7D231470313Q34508125-590483A4-D3C9-4EAB-897E-D6E14C7D8FADQ34612637-A87D9FA4-50D7-4C89-B033-D247682A7B63Q34617770-5D68FDAA-A209-4850-9052-324BD91AFC80Q34635978-DB0BF914-1F8D-41CE-ADF0-8E2330DA294EQ34803707-65301C8F-9882-4339-97FE-94E17C55F647Q34862104-5802EF06-4D89-4501-969E-B0FDC927AD9AQ35029920-3A4165B0-E651-4618-8915-08565421131CQ35095712-6BCF3AFF-C79D-4D3D-84D3-573C3FD52435Q35177618-B5029171-CC6E-47EC-A5D6-42F997E1717AQ35265135-AB3F8B79-E707-4C15-917A-C928BF2828C4Q35588845-3697F48E-A487-4F14-BFC9-251CFC380C96Q35603152-6AD168A7-5E9B-497F-A1CB-C48964908E5BQ35880618-F8AACA12-9F2B-4FB3-A1EF-57023BA9C6C4Q35889240-8E4251FB-7AA5-46AE-8648-9B587AB501B0Q36198150-645B2077-E582-4F76-8806-5DB5F60BDC8EQ37148167-85EC6E5D-A890-488A-A3B8-3BC48BB8CD81Q37194869-190B8327-223C-4067-9B0F-A848150A26F5Q37517482-90D05671-4B11-409F-8E48-D2C9CE27BD2EQ37574653-EE90BD75-BDAD-4821-98DF-0377486578A3Q37659113-D8436D9C-FF0E-48C0-9696-6B62B0F7BF5DQ37739362-68E87126-D985-464D-B4D4-123C4B63D1B5Q37850382-19751F78-74D8-4783-9E9A-C9425615291BQ37863518-C49219AC-DA82-4E1C-9AA0-4BD9A72B3063Q37892584-E9C407FB-F57A-41B4-B059-ECFD58C0C9A0Q37929157-816443A9-1CE3-4283-9A39-B3AD680C5039Q38015123-1A51B749-E54E-4503-93C6-10123115C0E4Q38056246-D998FC6B-A1C7-4A14-81E4-C0BD5B549699
P2860
Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Vaccination with synthetic ana ...... n from acute myeloid leukemia.
@ast
Vaccination with synthetic ana ...... n from acute myeloid leukemia.
@en
Vaccination with synthetic ana ...... n from acute myeloid leukemia.
@nl
type
label
Vaccination with synthetic ana ...... n from acute myeloid leukemia.
@ast
Vaccination with synthetic ana ...... n from acute myeloid leukemia.
@en
Vaccination with synthetic ana ...... n from acute myeloid leukemia.
@nl
prefLabel
Vaccination with synthetic ana ...... n from acute myeloid leukemia.
@ast
Vaccination with synthetic ana ...... n from acute myeloid leukemia.
@en
Vaccination with synthetic ana ...... n from acute myeloid leukemia.
@nl
P2093
P2860
P1433
P1476
Vaccination with synthetic ana ...... on from acute myeloid leukemia
@en
P2093
David A Scheinberg
Ellin Berman
Javier Pinilla-Ibarz
Jedd D Wolchok
Jianda Yuan
Joseph Jurcic
Lee M Krug
Mark G Frattini
Mark Weiss
Ronghua Zhang
P2860
P304
P356
10.1182/BLOOD-2009-10-250993
P407
P577
2010-04-16T00:00:00Z